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H I G H L I G H T S
 Nilotinib can reverse P-gp-mediated multidrug resistance of DOX in vitro and in vivo.
 Co-administration of nilotinib increase the accumulation of DOX and DOXol in heart.
 Combination with nilotinib will enhance the cardiotoxicity of DOX in xenograft mice.
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A B S T R A C T
The BCR-Abl tyrosine kinase inhibitor (TKI), nilotinib, was developed to surmount resistance or
intolerance to imatinib in patients with Philadelphia-positive chronic myelogenous leukemia. Recent
studies have shown that nilotinib induces potent sensitization to anticancer agents by blocking the
functions of ABCB1/P-glycoprotein (P-gp) in multidrug resistance (MDR). However, changes in P-gp
expression or function affect the cardiac disposition and prolong the presence of both doxorubicin (DOX)
and doxorubicinol (DOXol) in cardiac tissue, thus, enhancing the risk of cardiotoxicity. In this study, we
used a MDR xenograft model to evaluate the antitumor activity, tissue distribution and cardiotoxicity of
DOX when co-administered with nilotinib. This information will provide more insight into the
pharmacological role of nilotinib in MDR reversal and the risk of DOX cardiotoxicity. Our results showed
that nilotinib signiﬁcantly enhanced DOX cytotoxicity and increased intracellular rhodamine 123
accumulation in MG63/DOX cells in vitro and strongly enhanced DOX inhibition of growth of P-gp-
overexpressing MG63/DOX cell xenografts in nude mice. Additionally, nilotinib signiﬁcantly increased
DOX and DOXol accumulation in serum, heart, liver and tumor tissues. Importantly, nilotinib induced a
disproportionate increase in DOXol in cardiac tissue. In the co-administration group, CBR1 and AKR1A1
protein levels were signiﬁcantly increased in cardiac tissue, with more severe necrosis and vacuole
formation. These results indicate that nilotinib reverses P-gp- mediated MDR by blocking the efﬂux
function and potentiates DOX-induced cardiotoxicity. These ﬁndings represent a guide for the design of
future clinical trials and studies of pharmacokinetic interactions and may be useful in guiding the use of
nilotinib in combination therapy of cancer in clinical practice.
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ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nd/4.0/).1. Introduction
Doxorubicin (DOX) is an anthracycline ﬁrst extracted from
Streptomyces peucetius var. caesius in the 1970s. It is frequently
used in chemotherapy against non-Hodgkin’s and Hodgkin’s
lymphomas, multiple myeloma, sarcoma, pediatric cancers and
several solid tumors including breast, lung, gastric, ovarian, andarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Funes and Coronado, 2007); however, its clinical use is severely
limited due to the development of a progressive dose-dependent
cardiomyopathy that results in irreversible congestive heart
failure (Takemura and Fujiwara, 2007; Zuppinger et al., 2007).
Currently, total cumulative dose is the only criteria currently used
to predict the toxicity (Swain et al., 2003; Carvalho et al., 2009).
The application of DOX is further limited by lack of cytotoxicity
against cells expressing multidrug resistance (MDR) proteins
leading to the emergence of multidrug resistance (Booser and
Hortobagyi, 1994). Finding ways to maintain the efﬁcacy of DOX
and reduce toxicity has now become a major focus of DOX
research.
P-glycoprotein (P-gp), which is the product of the ABCB1 (or
MDR1) gene and is a member of a superfamily of ATP-binding
cassette (ABC) membrane transport protein, that was ﬁrst
characterized in multidrug resistant Chinese hamster ovary cells
by Juliano and Ling (Juliano and Ling, 1976). P-gp is a broad-
spectrum drug efﬂux pump that has 12 transmembrane regions
and two ATP-binding sites that bind either neutral or positively
charged hydrophobic drug substrates (Gottesman et al., 2002).
P-gp overexpression, which is the most frequent cause of MDR,
decreases the cytotoxicity of antitumor drugs including anthra-
cyclines, Vinca alkaloids, podophyllotoxins and taxanes (Krishna
and Mayer, 2000), thereby mediating resistance to these agents
and affecting their pharmacological behavior. In the past three
decades, the search for an effective P-gp inhibitor in the hope of
circumventing MDR has become an important focus of research. In
recent years, several TKIs including lapatinib (Dai et al., 2008),
geﬁtinib (Kitazaki et al., 2005), erlotinib (Shi et al., 2007), cediranib
(Tao et al., 2009), and sunitinib (Dai et al., 2009) have been
reported to inhibit the functions of P-gp, thereby overcoming
chemotherapy resistance in MDR cancer cells. Taken together,
these reports suggest that TKIs represent promising MDR
inhibitors.
However, P-gp is not an abnormal protein, P-gp is a robust
detoxiﬁcation protein that functions as a barrier against
xenobiotic entry in the intestine and at the blood–brain barrier
and is involved in drug excretion in the kidney, liver, and heart
(Huls et al., 2009; Solbach et al., 2008). Chuan reported that both
sodium Tan-IIA sulfonate and sodium danshensu inhibit the
expression and efﬂux functionality of placental P-gp, thereby
increasing the transplacental movement of digoxin, and enhanc-
ing the effectiveness of the drug used to treat congestive fetal
heart failure, while minimizing the risk of maternal toxicity
(Wang et al., 2014). After co-administration with a speciﬁc P-gp
inhibitor zosuquidar trihydrochloride (LY335979), the concentra-
tion of paclitaxel in the brain was signiﬁcantly increased, while
PET-CT imaging showed 2.3-fold increased levels of [18F]-geﬁtinib
in the brain of Abcb1a/1b;Abcg2-/- mice compared to wild-type
following intravenous administration of [18F]-geﬁtinib (1 mg/kg)
(Vlaming et al., 2015). Based on the results of tissue distribution
studies, it has been suggested that P-gp plays an important role
in the protection of the organism against potentially toxic
agents.
Nilotinib, a small-molecule BCR-Abl TKI, was developed to
overcome resistance or intolerance to imatinib in patients
with Philadelphia-positive chronic myelogenous leukemia
(Golemovic et al., 2005; Verstovsek et al., 2005). Previously, it
was reported that nilotinib signiﬁcantly reverses P-gp mediated
MDR in cancer cells by inhibiting its activity (Hegedus et al.,
2009; Tiwari et al., 2009; Villar et al., 2012). In this study,
we used a MDR cancer cell xenograft model to investigate
the tissue distribution and risk of cardiotoxicity of DOX
administered in combination with nilotinib to reverse drug
resistance.2. Materials and methods
2.1. Reagents
Doxorubicin was obtained from Pﬁzer Italia Srl (Latina, Italy).
Nilotinib was obtained from Novartis (Stein, Switzerland). Rhoda-
mine 123 (Rho 123), MTT, daunorubicin, and verapamil were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Monoclonal antibodies against P-gp (ab3366), BCRP [108312],
CBR1 (ab4148) and AKR1A1 (ab56635) were from Abcam (Hong
Kong). All the biochemical assay kits were purchased from Nanjing
Jiancheng Bioengineering Institute (Nanjing, China). Acetonitrile
and methanol (Tedia, CA, USA) were HPLC grade. Distilled,
deionized water was produced by a Milli-Q Reagent Water System
(Millipore, MA, USA). All other solvents and chemicals were
analytical grade or better.
2.2. Cell lines
All cell lines were cultured in vitro as monolayers in DMEM
medium supplemented with 10% heat-inactivated fetal bovine
serum, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37 C
in an atmosphere of 5% CO2 in air. The human osteosarcoma
parental cell line MG63 was obtained from the Institute of
Biochemistry and Cell Biology, Chinese Academy of Sciences
(Shanghai, China). The human MDR osteosarcoma cell line MG63/
DOX, which was selected in a step-wise manner by exposing drug-
sensitive MG63 cells to increasing doses of adriamycin, was kindly
provided by Dr. Shen Zan (Department of Oncology, Afﬁliated Sixth
People’s Hospital, Shanghai Jiao Tong University, Shanghai, China).
All cells were grown in drug-free culture medium for >2 weeks
before use in assays.
2.3. Animals
Athymic nude mice (BALB/c-nude), aged 4–5 weeks and
weighing 16–18 g, were obtained from Shanghai SLAC Laboratory
Animal Co. Ltd. (animal experimental license No. SCXK (hu) 2007-
0005), and used for the MG63/DOX cell xenografts. All animals
received sterilized food and water ad libitum. An acclimation
period of approximately 1 week was allowed between animal
arrival and tumor inoculation. All experiments were carried out in
accordance with the Guidelines for the Care and Use of Laboratory
Animals (Center of Experimental Animals, Shanghai Jiao Tong
University, China), and all protocols involving animals were
approved by the Ethics Committee for Animal Experiments.
2.4. Cytotoxicity tests
MTT assays were conducted as previously described to assess
the sensitivity of cells to drugs (Zhou et al., 2013a). Drug effects
were presented as the IC50 drug concentration and were
determined by XLFit software using equation 205. The degree of
resistance was estimated by dividing the IC50 of MG63/DOX cells by
that of MG63 cells; the fold-MDR reversal factor was calculated by
dividing the IC50 of the anticancer agent in the absence of nilotinib
by that obtained in the presence of nilotinib.
2.5. Rho123 accumulation
The effect of nilotinib on the intracellular accumulation of Rho
123 between MG63 and MG63/DOX cells was measured by ﬂow
cytometry as previously described (Mi et al., 2010). The P-gp
inhibitor verapamil was used as a positive control for MG63/DOX
cells. Cells in logarithmic growth were treated with or without
nilotinib (2.5, 5, and 10 mM) and verapamil (10 mM) at 37 C for 3 h
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The cells were then collected, centrifuged, and washed twice with
ice-cold PBS and resuspended in 500 mL PBS for ﬂow cytometric
analysis (BD FACSCalibur, Cellquest PRO, USA). A minimum of
10,000 cells were analyzed for each histogram generated.
2.6. Nude mouse xenograft model
The MG63/DOX inoculated nude xenograft model previously
established by us was used in this study (Zhou et al., 2013a). The
xenograft was found to maintain the MDR phenotype in vivo
and was extremely resistant to doxorubicin treatment. Brieﬂy,
MG63/DOX cells were suspended at 5 108 cells/mL in serum-free
DMEM/Matrigel (1:1). Then, 200 mL of these suspensions (1 107
cells) was injected subcutaneously into the right ﬂank of athymic
nude mice. When the tumors reached a mean diameter of 0.5 cm,
the mice were randomized into four groups and treated according
to various regimens: (a) saline (q3d  5); (b) doxorubicin (5 mg/kg,
i.v., q3d  5); (c) nilotinib (60 mg/kg, p.o., q3d  5); and (d)
doxorubicin (5 mg/kg, i.v., q3d  5) + nilotinib (60 mg/kg, p.o.,
q3d  5 given 1 h before injecting doxorubicin). The body weights
of the animals and the two perpendicular diameters (a and b) were
recorded every 3 days, and tumor volume (V) was estimated
according to the following formula: V (mm3) = 0.5 a  b2, where V is
the tumor volume, a is the long diameter, and b is the short
diameter. Tumor growth curves were generated according to
tumor volume and days post-inoculation. Tumor tissues were
excised from the mice and their weights were measured. The ratio
of growth inhibition (IR) was calculated according to the following
formula (Mi et al., 2010): IR(%) = 1  mean tumor weight of
experimental group/mean tumor weight of control group  100%.
2.7. Blood and tissue collection
Blood and tissue samples were collected at 3 h after the last
administration. Blood was obtained by orbital bleeding under CO2
anesthesia and collected in tubes; serum was separated within 1 h.
The animals were sacriﬁced by cervical dislocation to collect the
following tissues: heart, liver, spleen, kidney, and tumor. The
tissues were dissected out immediately, washed with ice-cold
saline, and homogenized with a glass tissue homogenizer in saline
to prepare 10% (w/v) homogenates, which were stored at 20 C
for analysis.
2.8. LC/MS/MS assay for doxorubicin and doxorubicinol concentration
in serum and tissue homogenates
The apparatus and chromatographic analysis conditions were
as previously described (Zhou et al., 2013b). Samples were
prepared by adding 30 mL buffer (aqueous solution of 0.1% formic
acid) and 120 mL of internal standard solution (40 ng/mL dauno-
rubicin) to 30 mL of mouse plasma and then vortexing for 1 min.
After centrifugation at 15,000  g for 5 min, 100 mL of the
supernatant was transferred to a sample vial and 5 mL was
injected into the LC/MS/MS for quantitative analysis.
The LC–MS–MS system was an Agilent 1200 liquid chromatog-
raphy and a 6410 B triple quadrupole mass spectrometer with an
electrospray ionization source. Data were analyzed by MassHunter
software (Agilent Corporation, MA, USA). Chromatography was
performed on a Zorbax XDB-C18 column (2.1mm  150 mm i.d.,
3.5 mm, Agilent Corporation, MA, USA) maintained at 35 C using
gradient elution with 5 mM ammonium formate and 0.1% formic
acid in puriﬁed water as solvent A and acetonitrile as solvent B.
The gradient program was then as follows: 0–1 min, 88% ! 25% A,
1–2.5 min, 25% ! 88% A, and 2.5–6 min, 88% A. The ﬂow rate was
set at 0.4 mL/min. Electrospray ionization (ESI) was performed inthe positive ion mode and quantiﬁed by the selected reaction
monitoring transitions as protonated precursor/product ion
transition of m/z 544/397 for doxorubicin, 546/399 for doxor-
ubicinol and 528/321 for IS (Daunorubicin), nebulizer and drying
gas were high-purity nitrogen and drying gas, gas temperature and
gas ﬂow were set at 350 C and 9.0 L/min.
2.9. Determination of biochemical indicators
To determine speciﬁc cardiac tissue toxicity, we investigated
parameters including creatine kinase (CK) and lactate dehydroge-
nase (LDH) in the heart tissue homogenate, which are used as
speciﬁc markers of cardiac damage in the clinic. One of the most
important mechanisms in DOX induced-cardiotoxicity is lipid
peroxidation. In the present study, lipid peroxidation was
expressed as nmoles of malondialdehyde (MDA, a product formed
by the peroxidation of membrane lipids) per milligram of protein.
The concentration of superoxide dismutase (SOD, catalyzes the
conversion of superoxide radicals to hydrogen peroxide, leading to
the formation of hydroxyl radicals) was also measured. The assays
were carried out using kits according to the manufacturer’s
instructions.
2.10. Histopathological studies
The left ventricular portion of heart tissues was ﬁxed in 10%
neutral buffered formalin. Sections (3–5 mm thickness) were
stained with hematoxylin and eosin for histological examination.
The histo-morphological evaluation of all the heart sections was
carried out in a blinded fashion by a pathologist who was unaware
of the treatment groups.
2.11. Western blot analysis
To identify the effects of nilotinib on P-gp expression, the
MG63/DOX cells were incubated with different concentrations of
nilotinib for 72 h. To clarify the possible mechanism of enhanced
cardiotoxicity, we determined the expression of CBR1 and AKR1A1
in heart tissue. The protein concentration was determined by BCA
assay, before being separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
polyvinylidene ﬂuoride membranes by electrophoretic transfer.
After blocking in 5% non-fat milk at room temperature for 2 h,
membranes were subsequently probed with primary antibodies at
4 C overnight. The membranes were then washed three times with
TBST buffer and incubated with secondary antibodies at room
temperature for 2 h. Immunoreactivity was visualized using an
electrochemiluminescence kit according to the manufacturer’s
instructions. The density of the immunoreactive bands was
analyzed using Image J2x (National Institutes of Health, Bethesda,
MD, USA).
2.12. Statistical analysis
All experiments were repeated at least three times and
differences were determined by using Student’s t-test and one-
way ANOVA with post-hoc analysis. Statistical signiﬁcance was set
at P < 0.05.
3. Results
3.1. Nilotinib reverses P-gp mediated MDR in MG63/DOX cells
To examine the effect of nilotinib on the reversal of P-gp-
mediated MDR in cancer cells, we ﬁrst determined the cytotoxicity
of nilotinib alone in MG63/DOX cell line with the MTT assay. More
Table 1
Effects of nilotinib on reversing P-gp mediated DOX resistance in osteosarcoma
cells.
IC10 SD, mmol/L
MG63 MG63/DOX
Nilotinib 2.267  1.81E-03 3.105  3.85E-04
IC50 SD, mmol/L (fold reversal)
MG63 MG63/DOX
Doxorubicin 0.044  2.71E-05 (1.00) 20.289  6.82E-03 (1.00)
+0.75 mM nilo 0.026  7.48E-06 (1.69) 0.752  3.84E-04 (26.98)
+1.5 mM nilo 0.025  1.22E-05 (1.76) 0.250  1.79E-04 (81.16)
+3 mM nilo 0.052  4.53E-05 (0.84) 0.144  1.43E-04 (140.90)
+10 mM vera 0.014  1.08E-05 (3.14) 0.191  5.27E-05 (106.23)
Fig. 1. Effect of nilotinib on the intracellular accumulation of Rho 123 in MG63/DOX
cells.
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nilotinib up to 3.1 mM; therefore, we used 0.75, 1.5 and 3 mM
nilotinib to reverse MDR in vitro. The doxorubicin IC50 in MG63
cells was 0.044  2.71E-05 mM; however, the concentration of
doxorubicin required to inhibit MG63/DOX cells by 50% was
20.289  6.82E–03 mM (Table 1). Thus, overexpression of P-gp
resulted in a signiﬁcant increase in resistance to doxorubicin (461-
fold). We then investigated the cytotoxic effect of DOX in MG63
and MG63/DOX cells in the presence of 0.75, 1.5, or 3 mM nilotinib.
The sensitivity to doxorubicin was unchanged when MG63 cells
were co-incubated with nilotinib at concentrations up to 3 mM. In
contrast, MG63/DOX cells were sensitized by low concentrations of
nilotinib. At concentrations of 0.75, 1.5 and 3 mM, nilotinib induced
increasingly effective reversal of resistance to doxorubicin (27-
fold, 81-fold and 141-fold, respectively). These results suggested
that nilotinib potently reverses P-gp-mediated resistance to
doxorubicin in vitro.
Cell survival was determined by MTT assay as described in the
Materials and Methods. Data represent the mean  SD of at least
three independent experiments performed in triplicate. The fold-
MDR reversal (values given in parentheses) was calculated by
dividing the anticancer drug IC50 for cells in the absence of nilotinib
or verapamil by that obtained in their presence.
3.2. Nilotinib enhances the accumulation of rho 123 in MG63/DOX
cells
To investigate the mechanism by which nilotinib inﬂuences the
function of P-gp, we determined the effect of nilotinib on
rhodamine accumulation in MG63/DOX cells (Fig. 1). In the
absence of nilotinib, the level of Rho 123 accumulation was low in
MG63/DOX cells and nilotinib restored the level of Rho 123
accumulation in a dose-dependent manner. These results showed
that nilotinib increases intracellular accumulation of the P-gp
substrate in cells expressing P-gp.
The accumulation of Rho 123 was measured by ﬂow cytometry
as described in the Materials and Methods. The intracellular
accumulation in MG63/DOX was signiﬁcantly increased in the
presence of nilotinib in a dose-dependent manner. Representative
data of least three independent experiments are shown.
3.3. Nilotinib reverses P-gp-mediated MDR in the nude mouse MDR
xenograft model
An established MG63/DOX cell xenograft model in nude mice
was used to evaluate the efﬁcacy of nilotinib in reversing
doxorubicin resistance in vivo. There were no signiﬁcant difference
in tumor size between animals treated with saline, nilotinib, or
doxorubicin, indicating the existence of DOX resistance in vivo.
However, the combination of nilotinib and doxorubicin produced asigniﬁcant inhibition of tumor growth compared with animals
treated with saline, nilotinib, or doxorubicin alone (P < 0.05;
Fig. 2 B and C). The ratio of tumor growth inhibition by the
combination was 28.4%. Furthermore, at the doses tested, no
mortality or apparent decrease in body weight was observed in the
combination treatment groups, suggesting that the combination
regimen did not increase the incidence of toxic side-effects
(Fig. 2A).
The experiment was carried out using athymic mice implanted
subcutaneously with MG63/DOX cells. A, changes in body weight
with time after inoculation (mean body weight for each group of 10
mice; bar, SD). B, changes in tumor volume with time (mean tumor
volume for each group in 10 mice after implantation; bars, SEM). C,
tumor sizes on the 29th day after implantation. The doses were as
follows: saline (0.2 mL, i.v., q3d  5); nilotinib (60 mg/kg, p.o.,
q3d  5); doxorubicin (5 mg/kg, i.v., q3d  5) and doxorubicin
(5 mg/kg, i.v., q3d  5) plus nilotinib (60 mg/kg, p.o., q3d  5, given
1 h before doxorubicin administration).
Tissue levels of DOX and DOXol in tumor-bearing mice after
different dosing regimens
To evaluate the inﬂuence of nilotinib on DOX distribution in
mice, the concentrations of DOX and its metabolite DOXol were
measured in all the major organs by LC–MS–MS before and after
the multiple dose combinations. Compared with the administra-
tion of DOX alone (5 mg/kg), the distribution of DOX was
signiﬁcantly increased in serum and heart, liver and tumor tissues
following treatment with DOX in combination 60 mg/kg nilotinib
(Fig. 3A). The distribution of the DOXol, the main metabolite of
DOX was also signiﬁcantly increased in serum, and heart and
tumor tissues (Fig. 3B). Interestingly, the increase in DOXol in heart
tissue was very signiﬁcant (P < 0.005).
Mice were treated with doxorubicin (5 mg/kg, i.v., q3d  5)
alone, and doxorubicin (5 mg/kg, i.v., q3d  5) plus nilotinib
(60 mg/kg, p.o., q3d  5, given 1 h before doxorubicin administra-
tion). Columns, mean value (n = 6); bars, SD. *, P < 0.05 versus (vs.)
the DOX group; **, P < 0.01 vs. the DOX group; ***, P < 0.005 vs. the
DOX group.
Fig. 2. Potentiation of antitumor effects of doxorubicin by nilotinib in a MG63/DOX cell xenograft model in athymic nude mice.
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analysis
LDH and CK levels were analyzed as measures of cardiotoxicity.
As shown in Fig. 4, there was no signiﬁcant difference between
animals treated with saline and those treated with nilotinib alone.
However, administration of DOX alone resulted in a signiﬁcant
increase in CK and LDH as compared to the saline group. After co-
administration of 60 mg/kg nilotinib, cardiotoxicity was still more
obvious, although there was no signiﬁcant difference compared
with the DOX alone group. Furthermore, MDA and SOD levels were
signiﬁcantly elevated in the DOX group and the combination
group, conﬁrming the important role of free radicals in DOX-
induced cardiotoxicity.
Mice were treated with saline (0.2 mL, i.v.), DOX (5 mg/kg, i.v.),
nilotinib (60 mg/kg, p.o.) or co-administration of nilotinib. All theFig. 3. Tissue levels of DOX and DOXol in tumor-btreatments were q3d  5. Columns, mean value (n = 6); bars, SD.
One-way ANOVA with post-hoc analysis; *, P < 0.05 vs. the saline
group; #, P < 0.05 vs. the nilotinib group.
Nilotinib enhanced doxorubicin-induced cardiotoxicity
evaluated in histopathological analyses
As shown in Fig. 5, normal morphology of the tissue was seen in
the saline group under light microscopy, with no signiﬁcant
difference in cardiac histology between animals treated with
nilotinib alone and those in the saline group. In contrast, DOX-
induced morphological changes in cardiac tissues were seen in the
DOX group. A cross-section of cardiac tissue of the rat showed
inﬁltration by numerous inﬂammatory cells with marked edema.
Severe necrosis and vacuoles were observed in the cardiac
tissues of mice following combined administration of nilotinib
and DOX.earing mice after different dosing regimens.
Fig. 4. Effects of nilotinib on creatine kinase (A, cardiac tissue homogenate), lactate dehydrogenase (B, serum), malondialdehyde (C, cardiac tissue homogenate) and
superoxide dismutase (D, cardiac tissue homogenate) activity.
Fig. 5. Microphotographs of H&E sections of cardiac tissue from tumor burdened mice after treatment with doxorubicin (5 mg/kg, i.v., q3d  5) plus nilotinib (60 mg/kg, p.o.,
q3d  5, given 1 h before doxorubicin administration). Mice were sacriﬁced for pathologic examination 24 h after the last administration. Control mice (A) showed normal
morphology; nilotinib-treated mice (B) showed no signiﬁcant pathological morphological changes; DOX treated mice (C) showed inﬁltration by numerous inﬂammatory
cells, marked edema and muscle ﬁber necrosis; mice treated with DOX co-administered with nilotinib (D) showed severe necrosis and vacuoles. Original magniﬁcation, 20.
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Fig. 6. Effect of nilotinib on the expression of P-gp and BCRP in MG63/DOX cells. 1:
MG63; 2: MG63/DOX; 3: MG63/DOX + 0.75 mM nilotinib; 4: MG63/DOX + 1.5 mM
nilotinib; 5: MG63/DOX + 3 mM nilotinib; 6: MG63/DOX + 10 mM nilotinib. Incuba-
tion of cells with nilotinib (0.75–10 mmol/L) for 72 h did not signiﬁcantly alter the
expression of P-gp or BCRP. This suggests that the MDR reversal effect of nilotinib in
MG63/DOX cells is independent of the inhibition of P-gp and BCRP expression.
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The reversal of P-gp-mediated MDR can be achieved either by
inhibiting its function or by lowering its expression. Therefore, we
determined the effect of nilotinib on the levels of P-gp and BCRP.
There were no signiﬁcant differences in the expression of BCRP
between MG63/DOX and the parent MG63 cells. However, P-gp
protein was signiﬁcantly upregulated in MG63/DOX cells com-
pared to MG63 cells. Furthermore, incubation of cells with
nilotinib (0.75–10 mmol/L) for 72 h did not signiﬁcantly alter the
expression of P-gp and BCRP in MG63/DOX cells (Fig. 6). These data
suggested that the reversal of MDR is induced by direct inhibition
of the efﬂux function of P-gp as opposed to downregulation of
protein expression.
3.6. AKR1 and CBR1 status and the effects of nilotinib
The previous results showed that the concentration of DOX in
heart tissue was signiﬁcantly increased after combined adminis-
tration with nilotinib (P < 0.05). Even more interestingly, the
concentration of DOXol was even more signiﬁcant (P < 0.005). The
two-electron reduction of the C-13 carbonyl group is the important
in the metabolization of DOX to DOXol. Candidate genes involved
in the formation of DOXol are AKR1A1, AKR1C3, CBR1, and CBR3.
Therefore, we examined the expression level of AKR1A1 and CBR1
in cardiac tissue. Our results showed that, compared with the
saline and nilotinib groups, AKR1A1 and CBR1 protein levels in the
DOX and combination groups were signiﬁcantly increased, with a
more signiﬁcant effect observed in the combination group (Fig. 7).Fig. 7. Effect of nilotinib on the expression of CBR1, AKR1A1 and P-gp in cardiac
tissue. Equal amount of protein were loaded for Western blot analysis as described
in the Materials and Methods. Independent experiments were performed at least
three times, and results from a representative experiment are shown.In contrast, there were no signiﬁcant differences in the P-gp
protein levels among the groups(Fig. 7). These results provide
evidence that the nilotinib-induced increase in cardiotoxicity is
mediated partly through increased formation of DOXol in a
mechanism that involves modulation of aldehyde reductase
expression.
4. Discussion
In this study, we used a MDR xenograft model to evaluate the
antitumor activity, tissue distribution and cardiotoxicity of DOX
when co-administered with nilotinib to gain more insight into the
pharmacological role of nilotinib in MDR reversal and the risk of
DOX cardiotoxicity. Our results indicate that nilotinib reverses P-gp
mediated MDR by blocking the efﬂux function and potentiates
DOX-induced cardiotoxicity.
The main mechanism that gives rise to MDR involved the
overexpression of ABC efﬂux transporters; therefore, one strategy
for MDR reversal is based on the use of anticancer drugs in
combination with ABC transporter inhibitors. Previous research
showed that nilotinib signiﬁcantly potentiated the cytotoxicity of
conventional chemotherapeutic agents in P-gp-overexpressing
MDR cells by interacting with P-gp and inhibiting its activity
(Tiwari et al., 2009; Tiwari et al., 2013). In the present study, we
showed that nilotinib exerted potent MDR reversal activity in P-gp
overexpressing MDR cells both in vitro and in vivo. Nilotinib in non-
toxic doses signiﬁcantly potentiated the cytotoxicity of DOX in
MG63/DOX cells, but had no signiﬁcant reversal effect in the parent
MG63 cells (Table 1). In vivo data showed that DOX in combination
with nilotinib markedly enhanced the antitumor activity of DOX in
a P-gp overexpressing tumor xenograft model (Fig. 2B and C). In the
mechanistic study, nilotinib signiﬁcantly enhanced intracellular
Rho123 accumulation in MDR cells (Fig. 1). However, expression of
P-gp and BCRP proteins in the MG63/DOX cells was not affected by
a 72-h treatment with 0.75, 1.5, 3, or 10 mmol/L nilotinib (Fig. 6).
Taken together, these data suggest that nilotinib reverses MDR by
directly inhibiting the function of P-gp rather than affecting its
expression.
Early reports raised questions of safety in the co-administration
of cytotoxic drugs with P-gp inhibitors (van Waterschoot et al.,
2009), since P-gp is not only responsible for the extrusion of
antineoplastic drugs from MDR tumoral cells, but also responsible
for the biodistribution and excretion of drugs from non-tumoral
cells expressing P-gp, such as cardiomyocytes (Solbach et al.,
2006). Co-administration of P-gp blockers (amiodarone, verapa-
mil, or PSC 833) signiﬁcantly increased DOX toxicity in cultured rat
cardiomyocytes (Estevez et al., 2000). Furthermore, DOX accumu-
lation was signiﬁcantly increased in the brain and liver and DOX
and DOXol retention in the heart were substantially prolonged in
mdr1a-knockout mice (van Asperen et al., 1999). These studies
indicated that co-administration of P-gp inhibitors may increase
the risk of DOX-induced cardiotoxicity by prolonging the exposure
of cardiac tissue.
Our previous pharmacokinetic studies have shown that single
co-administration of 40 mg/kg nilotinib with DOX enhanced AUC
(0–t) and Cmax of DOX by 1.24-fold and 1.96-fold, and its primary
circulating metabolite DOXol increased by 1.46-fold and 1.68-fold,
respectively. However, the cardiac tissue concentrations of DOX
and DOXol were signiﬁcantly decreased when combined with
40 mg/kg nilotinib (Zhou et al., 2013b). In accordance with
previous reports, it can be speculated that this result may be
due to stimulation of P-gp function and expression by short-term
exposure to DOX (Budde et al., 2011). In the present study, we
investigated the effect of nilotinib on the MDR reversal activity of
DOX in the nude mouse xenograft model. Simultaneously, the
concentrations of DOX and DOXol in the tissues were quantiﬁed by
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Signiﬁcantly increased accumulation of DOX in serum, heart, liver
and tumor tissues was observed (Fig. 3A); the same tendency was
observed for DOXol accumulation. Interestingly, a disproportion-
ately large increase in the accumulation of DOXol in cardiac tissue
was observed (Fig. 3B). LDH and CK levels were measured as
markers of cardiotoxicity. The results showed that administration
of DOX alone and in combination with nilotinib resulted in a
signiﬁcant increases in CK, LDH, MDA, and SOD as compared to the
levels detected in the saline and nilotinib groups; while there was
no signiﬁcant difference between the DOX group and the
combination group (Fig. 4). However, histopathological analysis
showed more severe necrosis and vacuoles in the cardiac tissue in
the combination group (Fig. 5).
The exact mechanism of DOX cardiotoxicity is somewhat
controversial. There are two main theories involve: (i) iron-related
free radicals and formation of the metabolite DOXol and (ii)
mitochondrial disruption, although these are somewhat interre-
lated (Thorn et al., 2011). The two-electron reduction of the C-13
carbonyl group is the main route of DOX metabolism, which is
implicated in DOX-induced cardiotoxicity (Mordente et al., 2009).
Candidate genes for the formation of DOXol are AKR1C3, AKR1A1,
CBR1, and CBR3 (Thorn et al., 2011; Olson et al., 2003). To further
investigate the role of CBR1 and AKR1A1 in DOX-induced
cardiotoxicity, we investigated the levels of CBR1 and AKR1A1
proteins in cardiac tissue. Compared with saline and nilotinib
groups, AKR1A1 and CBR1 protein levels were signiﬁcantly higher
in the DOX and combination groups, with the most signiﬁcant
effect observed in the combined treatment group (Fig. 7). These
observations indicate that the mechanism underlying the niloti-
nib-induced increase in cardiotoxicity is mediated by increased
formation of DOXol induced via the modulation of aldehyde
reductase expression.
In conclusion, nilotinib reverses P-gp mediated MDR in vitro and
in vivo, with the main reversal mechanism involving the inhibition
of P-gp function, resulting in elevated intracellular concentrations
of DOX. However, co-administration of nilotinib results in a
dramatic increase in systemic DOX and its metabolite DOXol with a
concomitantly increased risk of cardiotoxicity. Moreover, the
disproportionate increase in DOXol in cardiac tissue indicates
that secondary alcohol metabolites play an important role in the
development of DOX-induced cardiotoxicity. The upregulation in
AKR1A1 and CBR1 expression in cardiac tissue provides further
evidence in support of this mechanism. Consequently, our results
indicate that co-administration of a P-gp inhibitors may enhance
the risk of cardiotoxicity induced by DOX and should therefore
be considered carefully in further drug development and
application.
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